Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: Tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect

Molecular Therapy

Volumn 8, Issue 3, 2003, Pages 425-433

  Martel Renoir, Dominique ^a   Trochon Joseph, Véronique ^a,b   Galaup, Ariane ^a   Bouquet, Céline ^a   Griscelli, Franck ^a   Opolon, Paule ^a   Opolon, David ^a   Connault, Elisabeth ^a   Mir, Lluis ^a   Perricaudet, Michel ^a  

^a CNRS   (France)

^b BioAlliance Pharma   (France)

Author keywords

Angiostatin; Electroporation; K1 3 HSA; K1 5; pTet On; pTet tTS

Indexed keywords

ANGIOGENIC FACTOR; ANGIOSTATIN; ANTIMETASTATIC AGENT; CD31 ANTIGEN; DOXYCYCLINE; HUMAN SERUM ALBUMIN; PLASMID DNA; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; ELECTROPORATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC CODE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KRINGLE DOMAIN; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; MUSCLE CELL; NONHUMAN; NUDE MOUSE; PROTEIN SECRETION; SKELETAL MUSCLE; TRANSCRIPTION INITIATION; TRANSGENE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALIA; MUS MUSCULUS;

EID: 10744226243     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00201-6     Document Type: Article

References (47)

1. Carmeliet, P., and Jain, R. J. (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
2. Kerbel, R., and Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739.
3. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407.
4. O'Reilly, M. S., et al. (1994). Angiostatin, a novel angiogenesis inhibitor that mediates the suppression of metastases of Lewis lung carcinoma. Cell 79: 315-328.
5. Cao, Y., et al. (1996). Kringle domains of human angiostatin: Characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271: 29461-29467.
6. Ji, W. R., et al. (1998). Characterisation of kringle domains of angiostatin as antagonist of endothelial cell migration, an important process in angiogenesis. FASEB J. 15: 1731-1738.
7. Claesson-Welsh, L., et al. (1998). Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 95: 5579-5583.
8. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 6: 689-692.
9. Chen, Q. R., Kumar, D., Stass, S. A., and Mixon, J. (1999). Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59: 3308-3312.
10. Tanaka, T., Cao, Y., Folkman, J., and Fine, H. A. (1998). Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58: 3362-3369.
11. Indraccolo, S., et al. (2001). Effects of angiostatin gene transfer on functional properties and in vivo growth of Kaposi's sarcoma cells. Cancer Res. 61: 5441-5446.
12. Griscelli, F., et al. (1998). Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA 95: 6367-6372.
13. Chen, C., et al. (2000). Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum. Gene Ther. 11: 1983-1996.
14. Sauter, B. V., Martinet, O., Zhang, W. J., Mandeli, J., and Woo, L. C. (2000). Adenovirus mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Sci. Acad. USA 97: 4802-4807.
15. Feldman, A. L., et al. (2000). Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate endostatin levels in mice. Cancer Res. 60: 1503-1506.
16. Kuo, C. J., et al. (2001). Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Sci. Acad. USA 98: 4605-4610.
17. Gyorffy, S., Palmer, K., and Gauldie, J. (2001). Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am. J. Pathol. 159: 1137-1147.
18. Bouquet, C., et al. (2003). Systemic administration of a recombinant adenovirus encoding a HSA-angiostatin kringle 1-3 conjugate inhibits MDA-231 tumor growth and metastasization in a transgenic model of spontaneous eye cancer. Mol. Ther. 7: 174-184.
19. Ma, H. I., et al. (2002). Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res. 62: 756-763.
20. Cao, R., et al. (1999). Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 96: 5728-5733.
21. Rols, M. P., and Teissie, J. (1998). Electropermeabilization of mammalian cells to macromolecules: Control by pulse duration. Biophys. J. 3: 1415-1423.
22. Mir, L. M., et al. (1999). High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Sci. Acad. USA 96: 4262-4267.
23. Athanasopoulos, T., et al. (2000). Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aorticatheroma in apoE-deficient mice. Hum. Mol. Genet. 17: 2545-2551.
24. Mallat, Z., et al. (2001). Interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89: 41-45.
25. Nakano, A., et al. (2001). Cytokine gene therapy for myocarditis by in vivo electroporation. Hum. Gene Ther. 10: 1289-1297.
26. Satkauska, S., et al. (2002). Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol. Ther. 2: 133-140.
27. Lucas, M. L., Heller, L., Coppola, D., and Heller, R. (2002). IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol. Ther. 5: 668-675.
28. Indraccolo, S., et al. (2002). Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res. 62: 6099-6107.
29. Lo, W. D., Qu, G., Sferra, T. J., Clark, R., Chen, R., and Johnson, P. R. (1999). Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther. 10: 201-213.
30. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 12: 5547-5551.
31. Freundlieb, S., Schirra-Muller, C., and Bujard, H. A. (1999). Tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J. Gene Med. 1: 4-12.
32. Maruyama, H., Ataka, K., Higuchi, N., Sakamoto, F., Gejyo, F., and Miyazaki, J. (2001). Skin-targeted gene transfer using in vivo electroporation. Gene Ther. 23: 1808-1812.
33. Rizzuto, G., et al. (1999). Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Natl. Acad. Sci. USA 96: 6417-6422.
34. Perez, N., et al. (2002). Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: Application to interleukin 10 therapy in experimental arthritis. Hum. Gene Ther. 13: 2161-2172.
35. Nakamura, H., et al. (2001). Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int. 59: 2134-2135.
36. Chang, Y., and Prud'homme, G. J. (1999). Intramuscular administration of expression plasmids encoding interferon-γ receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J. Gene Med. 16: 415-423.
37. Cichon, T., Jamrozy, L., Glogowska, J., Missol-Kolka, E., and Szala, S. (2002). Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: Inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther. 9: 771-777.
38. Blezinger, P., et al. (1999). Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 4: 343-348.
39. Feldman, A. L., et al. (2001). Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 13: 1014-1020.
40. Eisterer, W., et al. (2002). Unfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5: 352-359.
41. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y., and Leboulch, P. (2002). Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther. 5: 345-351.
42. Marshall, E. (2002). Setbacks for endostatin. Science 295: 2198-2199.
43. MacDonald, N. J., Murad, A. C., Fogler, W. E., Lu, Y., and Sim, B. K. (1999). The tumor suppressing activity of angiostatin protein resides within kringle 1 to 3. Biochem. Biophys. Res. Commun. 264: 469-477.
44. Molema, G., van Veen-Hof, I., van Loenen-Weemaes, A. M., Proost, J. H., de Leij, L. F., and Meijer, D. K. (2001). Pharmacokinetics and whole body distribution of elastase derived angiostatin (K1-3) in rats. Int. J. Cancer 91: 1-7.
45. Beecken, W. D. C., et al. (2001). Effect of angiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Cancer Inst. 93: 382-387.
46. Mehvar, R., and Shepard, T. L. (1992). Molecular-weight-dependent pharmacokinetics of fluorescein-labeled dextrans in rats. J. Pharm. Sci. 9: 908-912.
47. Xu, Y. L., Swerlick, R. A., Sepp, N., Bosse, D., Ades, E. W., and Lawley, T. L. (1994). Characterization of expression and modulation of cell adhesion molecules on an immortalized human dermal microvascular endothelial cell line (HMEC-1). J. Invest. Dermatol. 102: 833-837.